CA2243507A1
(en)
*
|
1996-01-30 |
1997-08-07 |
Christopher J. Dinsmore |
Inhibitors of farnesyl-protein transferase
|
US5891889A
(en)
*
|
1996-04-03 |
1999-04-06 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
WO1997038665A2
(en)
*
|
1996-04-03 |
1997-10-23 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US6117641A
(en)
|
1996-04-11 |
2000-09-12 |
Mitotix, Inc. |
Assays and reagents for identifying anti-fungal agents and uses related thereto
|
JP2001513622A
(ja)
|
1996-04-11 |
2001-09-04 |
マイトティックス インコーポレーテッド |
抗菌剤の同定のためのアッセイおよび試薬、並びにそれらに関連する利用
|
US6727082B1
(en)
|
1996-04-11 |
2004-04-27 |
Gpc Biotech Inc. |
Assays and reagents for identifying anti-fungal agents, and uses related thereto
|
US5965570A
(en)
*
|
1996-09-13 |
1999-10-12 |
Schering Corporation |
Tricyclic piperidinyl compounds useful as inhibitors of farnesyl-protein transferase
|
US5972966A
(en)
*
|
1996-12-05 |
1999-10-26 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5932590A
(en)
*
|
1996-12-05 |
1999-08-03 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5977134A
(en)
*
|
1996-12-05 |
1999-11-02 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US6015817A
(en)
*
|
1996-12-05 |
2000-01-18 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5958940A
(en)
*
|
1997-09-11 |
1999-09-28 |
Schering Corporation |
Tricyclic compounds useful as inhibitors of farnesyl-protein transferase
|
WO1999027928A1
(en)
*
|
1997-12-04 |
1999-06-10 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
FR2780892B1
(fr)
*
|
1998-07-08 |
2001-08-17 |
Sod Conseils Rech Applic |
Utilisation d'inhibiteurs de prenyltransferases pour preparer un medicament destine a traiter les pathologies qui resultent de la fixation membranaire de la proteine g heterotrimerique
|
US6432959B1
(en)
|
1998-12-23 |
2002-08-13 |
Schering Corporation |
Inhibitors of farnesyl-protein transferase
|
FR2788274B1
(fr)
*
|
1999-01-11 |
2001-02-09 |
Aventis Pharma Sa |
Nouveaux derives de polyhydroxypyrazines, leur preparation et les compositions pharmaceutiques qui les contiennent
|
US6677332B1
(en)
|
1999-05-25 |
2004-01-13 |
Sepracor, Inc. |
Heterocyclic analgesic compounds and methods of use thereof
|
US6635661B2
(en)
|
2000-05-25 |
2003-10-21 |
Sepracor Inc. |
Heterocyclic analgesic compounds and methods of use thereof
|
US7361666B2
(en)
|
1999-05-25 |
2008-04-22 |
Sepracor, Inc. |
Heterocyclic analgesic compounds and methods of use thereof
|
WO2001068604A2
(en)
|
2000-03-14 |
2001-09-20 |
Sepracor, Inc. |
3-substituted piperidines comprising urea functionality, and methods of use thereof
|
AU2001216218A1
(en)
*
|
2000-05-25 |
2001-12-11 |
Sepracor, Inc. |
Heterocyclic analgesic compounds and method of use thereof
|
EP1296978A2
(de)
|
2000-06-30 |
2003-04-02 |
Bristol-Myers Squibb Company |
N-ureidoheterocycloaklylpiperidine als modulatoren der chemokinrezeptoraktivität
|
KR100432577B1
(ko)
*
|
2002-02-08 |
2004-05-24 |
주식회사유한양행 |
이미다졸 유도체의 제조방법
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
JP4137159B2
(ja)
|
2003-06-17 |
2008-08-20 |
ファイザー・インク |
セロトニン及びノルアドレナリン再取り込み阻害薬としてのn−ピロリジン−3−イル−アミド誘導体
|
GB0317665D0
(en)
|
2003-07-29 |
2003-09-03 |
Astrazeneca Ab |
Qinazoline derivatives
|
WO2005026150A1
(en)
|
2003-09-16 |
2005-03-24 |
Astrazeneca Ab |
Quinazoline derivatives as tyrosine kinase inhibitors
|
ATE550019T1
(de)
|
2005-05-17 |
2012-04-15 |
Merck Sharp & Dohme |
Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
|
ES2430139T3
(es)
|
2005-12-30 |
2013-11-19 |
Novartis Ag |
Compuestos de piperidina 3,5-sustituido como inhibidores de renina
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
EP2698157B1
(de)
|
2006-09-22 |
2015-05-20 |
Merck Sharp & Dohme Corp. |
Verfahren zur Behandlung von Fettsäure-Synthese-Hemmern
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
EP1921070A1
(de)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
EP2109608B1
(de)
|
2007-01-10 |
2011-03-23 |
Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. |
Amidsubstituierte indazole als poly-(adp-ribose)-polymerase (parp)-hemmer
|
WO2008093737A1
(ja)
|
2007-01-31 |
2008-08-07 |
Dainippon Sumitomo Pharma Co., Ltd. |
アミド誘導体
|
WO2008095847A1
(de)
|
2007-02-06 |
2008-08-14 |
Boehringer Ingelheim International Gmbh |
Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
MX2009009304A
(es)
|
2007-03-01 |
2009-11-18 |
Novartis Ag |
Inhibidores de cinasa pim y metodos para su uso.
|
CN101754965B
(zh)
|
2007-05-21 |
2014-03-19 |
诺华股份有限公司 |
Csf-1r抑制剂、组合物及使用方法
|
ES2541107T3
(es)
|
2007-06-25 |
2015-07-16 |
Novartis Ag |
Derivados de N5-(2-etoxietil)-N3-(2-piridinil)-3,5-piperidindicarboxamida para su uso como inhibidores de renina
|
US8389553B2
(en)
|
2007-06-27 |
2013-03-05 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
WO2009098061A1
(de)
|
2008-02-07 |
2009-08-13 |
Boehringer Ingelheim International Gmbh |
Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
AU2009247782C1
(en)
|
2008-05-13 |
2013-09-19 |
Astrazeneca Ab |
Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (N-methylcarbamoylmethyl) piperidin- 4-yl] oxy } quinazoline
|
JP5539351B2
(ja)
|
2008-08-08 |
2014-07-02 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法
|
EP2413932A4
(de)
|
2009-04-01 |
2012-09-19 |
Merck Sharp & Dohme |
Hemmer der akt-aktivität
|
US8765747B2
(en)
|
2009-06-12 |
2014-07-01 |
Dana-Farber Cancer Institute, Inc. |
Fused 2-aminothiazole compounds
|
US8658639B2
(en)
|
2009-06-24 |
2014-02-25 |
Dainippon Sumitomo Pharma Co., Ltd |
N-substituted-cyclic amino derivative
|
EP2488028B1
(de)
|
2009-10-14 |
2020-08-19 |
Merck Sharp & Dohme Corp. |
Substituierte piperidine zur erhöhung der p53-aktivität und ihre verwendung
|
EP2519517B1
(de)
|
2009-12-29 |
2015-03-25 |
Dana-Farber Cancer Institute, Inc. |
Typ-ii-raf-kinase-hemmer
|
BR112012023021A2
(pt)
|
2010-03-16 |
2016-05-31 |
Dana Farber Cancer Inst Inc |
compostos de indazol e seus usos
|
WO2011163330A1
(en)
|
2010-06-24 |
2011-12-29 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
CN103068980B
(zh)
|
2010-08-02 |
2017-04-05 |
瑟纳治疗公司 |
使用短干扰核酸(siNA)的RNA干扰介导的联蛋白(钙粘蛋白关联蛋白质),β1(CTNNB1)基因表达的抑制
|
KR102072631B1
(ko)
|
2010-08-17 |
2020-02-03 |
시르나 쎄러퓨틱스 인코퍼레이티드 |
짧은 간섭 핵산 (siNA)을 사용한 B형 간염 바이러스 (HBV) 유전자 발현의 RNA 간섭 매개 억제
|
US8883801B2
(en)
|
2010-08-23 |
2014-11-11 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
|
WO2012030685A2
(en)
|
2010-09-01 |
2012-03-08 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
EP3766975A1
(de)
|
2010-10-29 |
2021-01-20 |
Sirna Therapeutics, Inc. |
Rna-interferenz-vermittelte inhibition von genexpression unter verwendung kurzer interferierender nukleinsäure (sina)
|
WO2012087772A1
(en)
|
2010-12-21 |
2012-06-28 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
US20140046059A1
(en)
|
2011-04-21 |
2014-02-13 |
Piramal Enterprises Limited |
Process for the preparation of morpholino sulfonyl indole derivatives
|
US9023865B2
(en)
|
2011-10-27 |
2015-05-05 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
EP2822935B1
(de)
|
2011-11-17 |
2019-05-15 |
Dana-Farber Cancer Institute, Inc. |
Inhibitoren der c-jun-n-terminal-kinase (jnk)
|
US20150299696A1
(en)
|
2012-05-02 |
2015-10-22 |
Sirna Therapeutics, Inc. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
WO2014052563A2
(en)
|
2012-09-28 |
2014-04-03 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
EP2909194A1
(de)
|
2012-10-18 |
2015-08-26 |
Dana-Farber Cancer Institute, Inc. |
Hemmer der cyclinabhängigen kinase 7 (cdk7)
|
US10000483B2
(en)
|
2012-10-19 |
2018-06-19 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
|
WO2014063061A1
(en)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
ES2651347T3
(es)
|
2012-11-28 |
2018-01-25 |
Merck Sharp & Dohme Corp. |
Composiciones y métodos para el tratamiento del cáncer
|
CA2895504A1
(en)
|
2012-12-20 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as hdm2 inhibitors
|
US9540377B2
(en)
|
2013-01-30 |
2017-01-10 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as HDM2 inhibitors
|
CN105073728A
(zh)
|
2013-03-15 |
2015-11-18 |
全球血液疗法股份有限公司 |
化合物及其用于调节血红蛋白的用途
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
EP3057956B1
(de)
|
2013-10-18 |
2021-05-05 |
Dana-Farber Cancer Institute, Inc. |
Polycyclische inhibitoren der cyclin-dependent-kinase 7 (cdk7)
|
US20160264551A1
(en)
|
2013-10-18 |
2016-09-15 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of prolferative diseases
|
EA201992707A1
(ru)
|
2013-11-18 |
2020-06-30 |
Глобал Блад Терапьютикс, Инк. |
Соединения и их применения для модуляции гемоглобина
|
WO2015164614A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
WO2015164604A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
WO2016105528A2
(en)
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
US10550121B2
(en)
|
2015-03-27 |
2020-02-04 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
WO2016201370A1
(en)
|
2015-06-12 |
2016-12-15 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
EP4019515A1
(de)
|
2015-09-09 |
2022-06-29 |
Dana-Farber Cancer Institute, Inc. |
Hemmer von cyclinabhängigen kinasen
|
JOP20190055A1
(ar)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
US10851164B2
(en)
|
2017-04-13 |
2020-12-01 |
Aduro Biotech Holdings, Europe B.V. |
Anti-SIRPα antibodies
|
US10947234B2
(en)
|
2017-11-08 |
2021-03-16 |
Merck Sharp & Dohme Corp. |
PRMT5 inhibitors
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
WO2020033282A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
WO2020033284A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|